Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
74 hedge funds and large institutions have $293M invested in Avadel Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 12 closing their positions.
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
150% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 12
78% more call options, than puts
Call options by funds: $7.34M | Put options by funds: $4.11M
39% more capital invested
Capital invested by funds: $211M → $293M (+$81.9M)
32% more funds holding
Funds holding: 56 → 74 (+18)
16.06% more ownership
Funds ownership: 45.82% → 61.88% (+16%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$27.6M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
+$26.3M |
| 3 |
RI
RTW Investments
New York
|
+$6.08M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$5.71M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$4.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$8.12M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.9M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.93M |
| 4 |
Goldman Sachs
New York
|
-$1.52M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.42M |
AVDL Hedge Fund Activity: Q2 2020 in Review
74 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2020, worth a combined $293M — up 39% from $211M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new AVDL positions and 12 closed out — a net gain of 18 holders — while 27 added to existing stakes and 10 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $27.6M. The largest seller was Acuta Capital Partners, cutting an estimated $8.12M.
- 74 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2020, up from 56 in Q1 2020.
- Funds reported $293M of Avadel Pharmaceuticals stock for Q2 2020, up 39% quarter-over-quarter.
- 30 funds opened new Avadel Pharmaceuticals positions in Q2 2020 and 12 closed out, a net change of +18 holders.
- The largest Avadel Pharmaceuticals buyer in Q2 2020 was RA Capital Management, an estimated $27.6M added.
- The largest Avadel Pharmaceuticals seller in Q2 2020 was Acuta Capital Partners, an estimated $8.12M sold.
Based on aggregated 13F filings for Q2 2020.